Volume in Australia has been way up compared to normal over the past many days. Volume in the US has increased but only slightly compared to Australia. I would like to look at this as the start of something to come. We will see.
It is a given there will be an announcement of trial completion, so we are not within 40 days of receiving news of successful trial completion. Even without having results, it is somewhat of a safety & efficacy statement with the last formal dose duration being 12 weeks.
So announcement even of trial completion even without having results compiled is a positive news release for sure.
This is primarily a safety trial, with all signs of efficacy being checked. If PBT2 can show efficacy in Huntington's patients in under 6 months it will prove the statement I heard a famous researcher mutter about the competition after the final Alzheimer's ranking analysis, also applies to Huntington's ´´The others dont even come close´´
Sentiment: Strong Buy
One good thing is that it is that the last Reach2HD patients have done their 6 months within next 30 days and then it may take only some 2 months to get the main results, is PBT2 in humans good treatment in HD or not.
I keep thinking of that seen in Jaws where the reel on the fishing rod is starting to click really slowly, waiting for the shark to take the line.
Now with both trials funded to completion with excellent prospects of success, PRAN has to be worth more.
Sentiment: Strong Buy
Excuse me for trying to create (my own) enthusiasm . PRAN has done nearly 40000 shares today above $2.32. Not a big deal of course but a move above that price is the first technical barrier. Also, since last week's dip and rally PRAN ALMOST looks like it is forming an UPTREND! A news-less uptrend is greatly desired.
Molecular probe agent, simultaneously in the live mouse. This new revolutionary technology is expected to offer new insights into the relationships between bio-metal elements and associated bio molecules, and the roles they play in diseases such as diabetes and cancer.
Motomura, S. et al. Improved imaging performance of semiconductor Compton camera GREI makes for a new methodology to integrate bio-metal analysis and molecular imaging technology in living organisms, Journal of Analytical Atomic Spectrometry,
Motomura, S. et al. Improved imaging performance of semiconductor Compton camera GREI makes for a new methodology to integrate bio-metal analysis and molecular imaging technology in living organisms, Journal of Analytical Atomic Spectrometry, 2013.,doi: 10.1039/C3JA30185K
Metal elements and molecules interact in the body but visualizing them together has always been a challenge. Researchers from the RIKEN Center for Life Science Technologies have developed a new molecular imaging technology that enables them to visualize bio-metals and bio-molecules simultaneously in a live mouse. This new technology will enable researchers to study the complex interactions between metal elements and molecules Metal elements and molecules interact in the body but visualizing them together has always been a challenge. Researchers from the RIKEN Center for Life Science Technologies have developed a new molecular imaging technology that enables them to visualize bio-metals and bio-molecules simultaneously in a live mouse. This new technology will enable researchers to study the complex interactions between metal elements and molecules in living organisms.
Metal elements such as zinc, iron and copper are present in trace amounts in the body and play an important role in myriad biological processes including gene expression, signal transduction and metabolic reactions. Abnormalities in the behaviour of these elements often reflect abnormalities in associated bio-molecules and studying them together can offer great insight into many biological
Dr. Shuichi Enomoto, Dr. Shinji Motomura and colleagues, from the RIKEN Center for Life Science Technologies have developed a gamma-ray imaging camera enabling them to detect the gamma-rays emitted by multiple bio-metal elements in the body and study their behavior.
Their second prototype of the system, called GREI–II and presented today in the Journal of Analytical Atomic Spectrometry, enables them to visualize multiple bio-metal elements more than 10 times faster than before, and to do so simultaneously with positron emission tomography (PET).
In the study, the researchers were able to visualise two radioactive agents injected in a tumor-bearing mouse, as well as an anti-tumor antibody labelled with a PET
Very interesting indeed. No family history of cancer on my dad's side. And I guess that even if he does have some skin cancer now, he's in his mid-eighties, but he didn't have it earlier. I had my first skin cancer in my late forties, and my maternal aunt had it in her seventies. So maybe it's from my mother's side.
For my last skin cancer on my forehead, as they were stitching me up, I could feel my skin being pulled tighter and tighter. I was lying there thinking - I came in for a skin cancer excision, and I'm walking out with a mini face-lift. Not bad! I'm past 50, I need all the help I can get. And now for my next checkup in August, maybe I shouldn't worry so much. Bring it on!
If you are searching for information regarding the stock market, then you may want to research this.
Link:- doiopDOTcom/br29e2 (Remove DOT & use . )
They may not have to sell any more shares to raise capital if they have good results in the two trials they have going. A deal with a big Pharma may give them enough up front (say $350 million) which would be enough to carry them through to approval.
Zhidao, it is not only skin cancer but many different type of cancers. Here is one paper from this year from Taiwan:
Previous studies suggested a decreased risk of cancer among patients with Alzheimer's disease (AD). There is still a lack of data on the specific types of cancer, the risk factors, and the impact of cholinesterase inhibitors on developing cancer in AD.
We performed a nationwide population-based study of 6,960 patients with AD between 1997 and 2006 using Taiwan's National Health Insurance database. Patterns of cancer incidence in AD patients were compared with those of the general population using standardized incidence ratios (SIRs).
Patients with AD had a reduced risk of developing overall cancer [SIR = 0.88, 95% confidence interval (CI) = 0.80-0.97]. Specifically, patients with AD were protected from lung cancers (SIR = 0.75, 95% CI = 0.57-0.98), especially men (SIR = 0.61, 95% CI = 0.40-0.88). In subgroup analyses, women, patients aged 60-79 years, and those diagnosed as having AD for more than 1 year were more likely to be protected from cancers.
Our study demonstrates a decreased incidence of overall cancers in patients with AD, a finding lower than but consistent with Western countries. Patients with AD had a significantly decreased risk of lung cancer. Further investigation of genetic evidence linking AD to cancer is warranted.
Zhidao, skin cancer has emerged as a problem previously in LLYs semagacestat trial.
[In two pivotal Phase III trials, semagacestat was compared with placebo in more than 2,600 patients with mild-to-moderate Alzheimer's disease. Lilly has now reviewed data from a pre-planned interim analysis of semagacestat studies. This interim analysis showed that, as expected, cognition and the ability to complete activities of daily living of placebo-treated patients worsened. However, by these same measures, patients treated with semagacestat worsened to a statistically significantly greater degree than those treated with placebo. In addition, data showed semagacestat is associated with an increased risk of skin cancer compared with those who received placebo.]
I don't know if there is any link, but that gamma secretase inhibitor also affected Notch, which they think caused the problems from what I recall.
Sentiment: Strong Buy